abatacept placebo

DRUG3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Bristol-Myers Squibb

Conditions

Lupus Erythematosus, SystemicLupus NephritisRheumatoid Arthritis

Phase 2

Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

CompletedNCT00774852

National Institute of Allergy and Infectious Diseases (NIAID)Lupus Erythematosus, Systemic, Lupus Nephritis

Start: 2008-11-30End: 2014-06-30Updated: 2016-02-08

Phase 3

Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis

CompletedNCT01142726

Bristol-Myers SquibbRheumatoid Arthritis

Start: 2010-12-31End: 2014-10-31Updated: 2016-01-14

Effects of Abatacept in Patients With Early Rheumatoid Arthritis

CompletedNCT02504268

Bristol-Myers SquibbRheumatoid Arthritis

Start: 2015-09-03End: 2020-03-19Updated: 2021-06-28

Related Papers

Baseline interleukin-10 levels as a predictive biomarker for achieving clinical response with abatacept in disease-modifying antirheumatic drug-naive and anticitrullinated protein antibody-positive patients with early rheumatoid arthritis.

2026-02-24

Association Between Abatacept Exposure Levels and Infection Occurrence in Patients With Rheumatoid Arthritis: Post Hoc Analysis of the AVERT-2 Study

The Journal of Rheumatology2025-01-151 citations

The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study.

2023-04-222 citations

Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis.

2023-03-038 citations

Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis

RMD Open2022-12-013 citations

Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept.

2022-02-1611 citations

Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials

Lara D. Veeken2019-12-0210 citations

Determining MRI Inflammation Targets When Considering a Rheumatoid Arthritis Treat-to-Target Strategy: Results of a Randomized, Placebo-Controlled Trial.

2019-07-055 citations

Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study

RMD Open2019-02-019 citations

On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis

Rheumatology International2018-10-205 citations

Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis.

2016-02-1018 citations

Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis.

2015-03-10140 citations

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period.

2014-11-03182 citations